Networking +
Policy +
Member
Career
Choose
Colorado BioScience Association is thrilled to announce the first round of companies selected to present at the 2026 Rocky Mountain Life Sciences Investor and Partnering Conference in Vail September 30-October 2.
The application period for presenting companies has now closed. The complete roster of presenting companies will be announced June 26, 2026.
The 2026 conference will feature close to 40 presenting companies, primarily from Colorado, representing the depth of innovation across the Rocky Mountain West. They are advancing clinical pipelines, building scalable platforms, and creating value across biotech, pharma, medical device, diagnostics, digital health, and animal health.
Meet the Presenting Companies
Biotech + Pharma: Pre-Seed and Seed
Funding Sought: $3M Seed
Biota delivers a fully integrated solution to modernize PFAS testing through two complementary products—combining breakthrough lab efficiency with real-time field intelligence. Biota is not just improving PFAS testing—we are rebuilding the infrastructure of environmental diagnostics to match the speed, scale, and impact required to protect human health.
Recent News:
Awarded $250k Colorado OEDIT Advanced Industries Grant
Awarded $305k National Institute of Environmental Health Sciences SBIR Phase I Grant
Funding Sought: $3M Seed
Illumen Therapeutics, a University of Colorado spinout, is pursuing a novel therapeutic strategy to treat aggressive cancers, such as colorectal and pancreatic cancers, by restoring functional p53 through inhibiting the enzyme PARN. This breakthrough in oncology drug development avoids the historical problems exhibited with MDM2 inhibitors.
Recent News:
Funding Sought: $5M Seed
Intero Biosystems has developed the first induced pluripotent stem cell (iPSC)-derived Human Intestinal Organoid to contain the major cell types of the human intestine mimicking the organ’s spatial organization and function. GastroScreen can be used in preclinical assays, disease modeling, toxicity testing, and in functional tests to predict how drugs will behave in humans, mitigating risk, saving money, and identifying safer more effective compounds.
Recent News:
Funding Sought: $1.5M Seed
Jura Health is pioneering patient-centered solutions that combine genomic diagnostics, care navigation, and social determinant support for patients with rare and complex conditions that do not have access to leading medical and research institutions. By shortening the 6-year diagnostic odyssey to 5 weeks, we save healthcare costs ranging between $80,000 to over $500,000 per patient and improve medical management in up to 70% of cases.
Recent News:
Funding Sought: $2M Pre-Seed
Wave Bye provides a proactive solution for menstrual pain and heavy bleeding by targeting the biological pathway that causes symptoms before they begin. Instead of treating cramps after they start, the product is designed to be taken shortly before menstruation to interrupt the prostaglandin cascade responsible for both pain and excess bleeding.
Recent News:
Received Investment at Emmeline Ventures' Culture Shifting Deal-Making Summit
Biotech + Pharma: Series A and B
Funding Sought: $23M Series A
SiVEC Biotech is advancing first-in-class therapies by harnessing their groundbreaking BactPac™ drug delivery platform. BactPac uses the power of engineered bacteria to overcome the biggest hurdles in developing and commercializing biologics, achieving safe, targeted delivery with the added advantage of simple, scalable manufacturing. BactPac delivers a diverse array of biologics, including mRNA, siRNA, proteins, and CRISPR gene editors, with precision and safety that surpass traditional delivery methods.
Recent News:
SiVEC Biotechnologies and RheumaGen Announce Partnership to Advance In Vivo Gene-Editing Therapies
Think Bioscience is a privately held small molecule drug discovery company based in Boulder, Colorado, focused on developing therapeutics against targets that have historically been considered "undruggable". The company's team combines expertise in synthetic biology, protein biophysics, applied enzymology, computational chemistry, and medicinal chemistry to launch first-in-class program for diseases with high unmet need.
Recent News:
Medtech: Pre-Seed and Seed
Funding Sought: $5M Seed
ExOcular is revolutionizing the management of severe eye diseases. We're developing a portfolio of blood-based multiplex tests built on exosome-based, disease-specific biomarkers. These tests provide early, and actionable insights, paving the way for personalized and transformative patient care. We empower physicians with unparalleled insights to deliver earlier, more effective treatments.
Recent News:
Joined Wyss Institute at Harvard University Diagnostic Accelerator
Medtech: Series A and B
Funding Sought: $2M Series A
Burst Diagnostics is an early-stage diagnostics company translating laboratory-grade immunoassays into rapid, cost-effective formats for use in point-of-need settings. Its proprietary Capillary Driven Immunoassay (CaDI) platform delivers ten-minute quantitative results through an easy-to-use format, supporting both Burst-branded products and custom assay solutions. BurstDX will begin with the launch of a testosterone test before expanding to additional hormone targets for both men and women long-term. The platform enables detection across a broad range of targets and sample types in clinical and non-clinical applications, including food safety, veterinary diagnostics, wellness, environmental monitoring, and beyond.
Recent News:
Burst Diagnostics and FemmeLoop Secure NIH Funding to Advance At-Home Diagnostics for Perimenopause
Lazzaro Medical addresses the lack of effective, standardized surgical solutions for patients suffering from expiratory central airway collapse (ECAC), including tracheobronchomalacia (TBM). Lazzaro Medical has developed the Lazzaro Medical Scaffold System ™, a first-of-its-kind, anatomically optimized implant designed specifically for reinforcement of the central airway during tracheobronchoplasty. Unlike generic mesh, the system is engineered for airway
anatomy, enabling improved visualization, controlled tensioning, and more consistent suturing during robotic and open procedures.
Recent News:
Received FDA Breakthrough Device Designation for the LM Scaffold System
Lazzaro Medical wins $2.4M SBIR grant from National Institutes of Health
Colorado Success Stories
Meet public and VC-backed companies that have grown rapidly in Colorado and raised significant capital.
Ambrosia Biosciences accelerated from stealth to a $100M Series B in less than 18 months. The company launched with a team of world-class medicinal chemists from Array Biopharma, which was acquired by Pfizer in 2019 for $11.8 billion in cash, the largest acquisition of a venture-backed life sciences company in the history of Colorado. Ambrosia, a privately held drug discovery company, is developing orally delivered, small molecule-based therapies for obesity and other metabolic disorders.
Recent News:
Ambrosia Biosciences Announces $25MM Series A Financing, Including Strategic Investment by Merck
Nick Traggis and Ambrosia Biosciences: Building on Array Biopharma’s Legacy
Biodesix (NASDAQ: BDSX)
Biodesix recently celebrated the fifth anniversary of its IPO and announced continued progress toward profitability. Recognized nationally and in Colorado for its executive leadership and as a top workplace, Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. To deliver on the company’s mission to transform patient care and improve outcomes through personalized diagnostics, Biodesix provides advanced diagnostic tests and custom development services.
Recent News:
Biodesix Recognized as a USA TODAY Top Workplace for Third Consecutive Year
Biodesix Celebrates 5 Year IPO Anniversary at Nasdaq Closing Bell Ceremony
Colorado Success Stories Snapshot: Includes 2022 and 2024 Presenting Companies
